Physician profile
Stanley M Lee
NPI 1073505830
$1,001.00
in general payments reported to CMS, 2019-2025
18 companies · $18.49 in 2025
The $18.49 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $91.26 · 2021: $414 · 2022: $30.63 · 2023: $55.00 · 2025: $18.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $73.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $73.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $155.64 | 2019-2023 | Farxiga |
| W. L. Gore & Associates, INC. | $136.13 | 2019 | |
| Bard Peripheral Vascular, INC. | $131.01 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $122.61 | 2021 | |
| Mylan Specialty L.P. | $85.89 | 2021 | |
| Amgen INC. | $61.88 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $47.91 | 2019-2020 | |
| Covidien LP | $47.24 | 2019 | |
| Opko Pharmaceuticals, LLC | $39.68 | 2019-2020 | |
| Travere Therapeutics, INC. | $33.59 | 2023 | |
| Veloxis Pharmaceuticals, INC. | $31.45 | 2019 | |
| Daiichi Sankyo INC. | $19.64 | 2019 | |
| Aurinia Pharma U.S., INC. | $18.49 | 2025 | Lupkynis |
| Fresenius USA Marketing, INC. | $17.66 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.72 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomerieux INC | $13.62 | 2019 | |
| Shire North American Group INC | $13.02 | 2019 | |
| Alexion Pharmaceuticals, INC. | $11.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.